SC
ACIU icon

Saturna Capital’s AC Immune ACIU Stock Holding History

Saturna Capital’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,100
Closed -$55K – 169
2021
Q4 		$55K Hold
11,100
– – ﹤0.01% 172
2021
Q3 		$74K Sell
11,100
-20,500
-65% -$147K ﹤0.01% 174
2021
Q2 		$251K Buy
31,600
+5,500
+21% +$38K 0.01% 162
2021
Q1 		$199K Buy
+26,100
New +$186K ﹤0.01% 161

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Saturna Capital's ACIU Position: Q1 2022 in Review

Saturna Capital sold out of AC Immune (ACIU) in Q1 2022, closing a stake of 11,100 shares — an estimated $55K sold.

Saturna Capital first reported a position in ACIU in Q1 2021 and held it in 4 quarters. The position peaked at $251K in Q2 2021. 36 funds tracked by Wall St. Rank hold ACIU as of Q1 2022.

  • Saturna Capital reported no remaining AC Immune position as of Q1 2022 after selling out during the quarter.
  • Saturna Capital sold 11,100 AC Immune shares in Q1 2022, an estimated $55K.
  • Saturna Capital first reported a position in AC Immune in Q1 2021 and held it in 4 quarters.
  • Saturna Capital's AC Immune position peaked at $251K in Q2 2021.
  • 36 funds tracked by Wall St. Rank held AC Immune as of Q1 2022.

Based on Saturna Capital's 13F filing for Q1 2022, filed 10 May 2022.